Literature DB >> 22554505

The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.

Laura B Peterson1, Jeffrey D Eskew, George A Vielhauer, Brian S J Blagg.   

Abstract

Heat shock protein 90 (Hsp90) has emerged as a promising therapeutic target for the treatment of cancer. Several Hsp90 inhibitors have entered clinical trials. However, some toxicological detriments have arisen, such as cardiotoxicity resulting from hERG inhibition following the administration of Hsp90 inhibitors. We sought to investigate this toxicity as hERG has been previously reported as a client protein that depends upon Hsp90 for its maturation and functional trafficking. In this study we show that hERG depends upon a single Hsp90 isoform. hERG preferentially co-immunoprecipitated with Hsp90α, and genetic knockdown of Hsp90α, but not Hsp90β, resulted in a trafficking-defective hERG channel. This study demonstrates the importance of delineating the isoform dependence of Hsp90 client proteins and provides rationale for the design of isoform-selective Hsp90 inhibitors that avoid detrimental effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554505      PMCID: PMC3557513          DOI: 10.1021/mp300138n

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  27 in total

Review 1.  Functional specificity of co-chaperone interactions with Hsp90 client proteins.

Authors:  Daniel L Riggs; Marc B Cox; Joyce Cheung-Flynn; Viravan Prapapanich; Patricia E Carrigan; David F Smith
Journal:  Crit Rev Biochem Mol Biol       Date:  2004 Sep-Dec       Impact factor: 8.250

Review 2.  HERG channel trafficking.

Authors:  Eckhard Ficker; Adrienne Dennis; Yuri Kuryshev; Barbara A Wible; Arthur M Brown
Journal:  Novartis Found Symp       Date:  2005

3.  Hsp90alpha chaperones large C-terminally extended proteolytic intermediates in the MHC class I antigen processing pathway.

Authors:  Jun Kunisawa; Nilabh Shastri
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

4.  The HSP90 family of genes in the human genome: insights into their divergence and evolution.

Authors:  Bin Chen; William H Piel; Liming Gui; Elspeth Bruford; Antónia Monteiro
Journal:  Genomics       Date:  2005-11-02       Impact factor: 5.736

5.  GCUNC45 is the first Hsp90 co-chaperone to show alpha/beta isoform specificity.

Authors:  Ahmed Chadli; Sara J Felts; David O Toft
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

6.  Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation.

Authors:  C Didelot; D Lanneau; M Brunet; A Bouchot; J Cartier; A Jacquel; P Ducoroy; S Cathelin; N Decologne; G Chiosis; L Dubrez-Daloz; E Solary; C Garrido
Journal:  Cell Death Differ       Date:  2008-02-01       Impact factor: 15.828

7.  Co-chaperone FKBP38 promotes HERG trafficking.

Authors:  Valerie E Walker; Roxana Atanasiu; Hung Lam; Alvin Shrier
Journal:  J Biol Chem       Date:  2007-06-14       Impact factor: 5.157

Review 8.  Hsp90: a novel target for the disruption of multiple signaling cascades.

Authors:  Stephanie C Bishop; Joseph A Burlison; Brian S J Blagg
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

9.  N-linked glycosylation sites determine HERG channel surface membrane expression.

Authors:  K Petrecca; R Atanasiu; A Akhavan; A Shrier
Journal:  J Physiol       Date:  1999-02-15       Impact factor: 5.182

10.  Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.

Authors:  Stefan H Millson; Andrew W Truman; Attila Rácz; Bin Hu; Barry Panaretou; James Nuttall; Mehdi Mollapour; Csaba Söti; Peter W Piper
Journal:  FEBS J       Date:  2007-08-06       Impact factor: 5.542

View more
  22 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

Review 3.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

4.  KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.

Authors:  Weiya Liu; George A Vielhauer; Jeffrey M Holzbeierlein; Huiping Zhao; Suman Ghosh; Douglas Brown; Eugene Lee; Brian S J Blagg
Journal:  Mol Pharmacol       Date:  2015-05-04       Impact factor: 4.436

5.  Development of radamide analogs as Grp94 inhibitors.

Authors:  Aaron Muth; Vincent Crowley; Anuj Khandelwal; Sanket Mishra; Jinbo Zhao; Jessica Hall; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-06-12       Impact factor: 3.641

6.  Structures of Hsp90α and Hsp90β bound to a purine-scaffold inhibitor reveal an exploitable residue for drug selectivity.

Authors:  John D Huck; Nanette L S Que; Sahil Sharma; Tony Taldone; Gabriela Chiosis; Daniel T Gewirth
Journal:  Proteins       Date:  2019-06-12

7.  Endoplasmic Reticulum-resident Heat Shock Protein 90 (HSP90) Isoform Glucose-regulated Protein 94 (GRP94) Regulates Cell Polarity and Cancer Cell Migration by Affecting Intracellular Transport.

Authors:  Suman Ghosh; Heather E Shinogle; Nadezhda A Galeva; Rick T Dobrowsky; Brian S J Blagg
Journal:  J Biol Chem       Date:  2016-02-12       Impact factor: 5.157

Review 8.  Regulation and function of the human HSP90AA1 gene.

Authors:  Abbey D Zuehlke; Kristin Beebe; Len Neckers; Thomas Prince
Journal:  Gene       Date:  2015-06-10       Impact factor: 3.688

9.  Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β.

Authors:  Kendrick H Yim; Thomas L Prince; Shiwei Qu; Fang Bai; Patricia A Jennings; José N Onuchic; Emmanuel A Theodorakis; Leonard Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-27       Impact factor: 11.205

10.  Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

Authors:  Sanket J Mishra; Suman Ghosh; Andrew R Stothert; Chad A Dickey; Brian S J Blagg
Journal:  ACS Chem Biol       Date:  2016-12-13       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.